|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | G01N 33/543 | |
| G01N 33/566 | |||
| G01N 33/574 | |||
| G01N 33/68 |
| (11) | Number of the document | 3283882 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16780526.6 |
| Date of filing the European patent application | 2016-04-12 | |
| (97) | Date of publication of the European application | 2018-02-21 |
| (45) | Date of publication and mention of the grant of the patent | 2020-12-16 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/027014 |
| Date | 2016-04-12 |
| (87) | Number | WO 2016/168133 |
| Date | 2016-10-20 |
| (30) | Number | Date | Country code |
| 201562149333 P | 2015-04-17 | US |
| (72) |
AYERS, Mark, US
LUNCEFORD, Jared, US
LOBODA, Andrey, US
NEBOZHYN, Michael, US
MCCLANAHAN, Terrill, K., US
HIRSCH, Heather, US
|
| (73) |
Merck Sharp & Dohme Corp.,
126 East Lincoln Avenue, Rahway, NJ 07065-0907,
US
|
| (54) | BLOOD-BASED BIOMARKERS OF TUMOR SENSITIVITY TO PD-1 ANTAGONISTS |
| BLOOD-BASED BIOMARKERS OF TUMOR SENSITIVITY TO PD-1 ANTAGONISTS |